
Introducing FactsR™ by Corti -- the First Clinical Reasoning Layer for Ambient AI in Healthcare
Real-time, recursive, fact-first architecture reduces AI-generated "note bloat" by 65 percent and minimizes post-visit edits - transforming passive documentation into active clinical intelligence.
COPENHAGEN, Denmark, June 11, 2025 /CNW/ -- Corti, the leading infrastructure layer for building clinical-grade AI in healthcare, today announced the launch of FactsR™, a breakthrough real-time agentic reasoning system for clinical consultations. Designed with ambient documentation in mind, FactsR™ reduces general purpose AI driven "note bloat" by 65 percent, keeping records precise, relevant, and tightly aligned with the actual clinical conversation. By minimizing post-visit edits and transforming passive transcripts into active clinical intelligence, FactsR™ sets a new benchmark for ambient AI in healthcare - while unlocking the path to real-time decision support at the point of care.
Unlike traditional LLM pipelines retrofitted for healthcare, FactsR is powered by Corti's recursive fact-first reasoning loop - a purpose-built engine designed to surface, validate, and structure clinical knowledge in real time as conversations unfold. Delivered as a modular API, it enables developers to embed clinical-grade intelligence directly into their healthcare applications - creating safer, leaner, and more trusted AI experiences at the point of care.
Why a recursive approach matters
Traditional ambient solutions pipe raw transcripts through generic models after the consultation has ended, producing verbose, error‑prone summaries that clinicians spend up to three hours a week correcting.
FactsR reflects a foundational shift in AI system design - from passive summarization to active reasoning. It allows developers to build AI that offers more concise, accurate results that clinicians can interact with live, in consultations and beyond. The process unfolds in four key stages:
Listen and Extract in Real Time
As the consultation unfolds, FactsR continuously identifies and surfaces structured clinical "facts" - such as symptoms, vitals, medications, and social history - while the conversation unfolds, live.
Vet and Refine with Specialized AI
Each fact is automatically reviewed and improved through an AI-driven feedback loop. If something is unclear, the system refines it until it is accurate, consistent, and ready to use - no guesswork, no clutter.
Clinician-in-the-Loop
Clinicians can quickly review, accept, or adjust facts as they go. Early adopters report far fewer post-visit edits and rarely need to add missing information after the consultation. This design keeps clinicians in control, ensuring that AI augments rather than replaces clinical judgment.
Generate EHR-Ready Notes
Once the facts are finalized, the system assembles a clean, concise summary - free from long, verbose summaries or irrelevant content.
This means:
Less Screen Time
Early trials show that users spend minutes, not hours, on corrections
Better Patient Focus
Real‑time reasoning means decisions stay in the consultation, not in hindsight.
Audit‑Ready Transparency
Every fact carries a timestamp, confidence score, and link back to the conversation.
Healthcare AI that Delivers
Reduces general purpose AI driven "note bloat" by 65 percent.
The innovation behind FactsR has been published together with evaluation results on the public benchmark Primock57 dataset. The evaluation shows that FactsR increases clinical completeness by 13 percent - capturing significantly more of the relevant medical information compared to traditional ambient scribes - while reducing note bloat by over 65 percent with a clinician-in-the-loop.
"Corti's system already does an excellent job capturing clinical details accurately, even in natural conversation," said a beta user from an IT team in a regional Danish hospital. "But when testing this new innovation, what really stood out was the shift toward structured, recursive fact extraction. It goes beyond basic transcription to surface the right clinical facts in real time - exactly what busy clinicians need to stay focused and cut down on documentation overload."
"FactsR exemplifies Corti's core philosophy: healthcare AI must be purpose-built, real-time, and accountable," said Lars Maaløe, CTO and co-founder of Corti.ai. "By breaking conversations into structured clinical facts and validating each one through recursive reasoning, FactsR elevates ambient documentation into a foundation for real-time clinical intelligence. When AI can listen, understand, and reason with medical context, it becomes more than a scribe - it becomes a trusted collaborator. With a developer-friendly API, we're enabling any healthtech company to embed this capability directly into their applications - safely, scalably, and in minutes."
Availability
FactsR is offered today through a consumption‑based API with enterprise‑grade HIPAA and GDPR compliance. Developers can start for free at docs.corti.ai and access SDKs for safe and effective app building in as little as 30 minutes. A self‑hosted option for on‑prem or sovereign‑cloud deployments enters limited preview this summer.
About Corti.ai
Corti.ai is a research and development company building state‑of‑the‑art AI foundation models for healthcare. The company's mission is to eliminate administrative hurdles and bring expert‑level reasoning to every corner of the globe, driving down costs and improving quality of care. Corti's models integrate seamlessly into any healthcare application through SDKs and APIs, enabling vendors, providers and payers to leverage safe, cutting‑edge AI across an extensive range of clinical use cases.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
7 hours ago
- Cision Canada
IDC Report: Huawei Ranks No.1 in Global Wrist-Worn Market in Q1
H u awei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /CNW/ -- According to the latest IDC Worldwide Quarterly Wearable Device Tracker data, Huawei ascended to the top position in the global wrist-worn device market in Q1 2025, while maintaining robust growth momentum and retaining its leadership in shipment volume within China. Additionally, as of 5 June 2025, Huawei's cumulative global wearable shipments have exceeded 200 million units. Five Product Series Catering to Global Users' Diverse Scenario Needs Huawei wearables integrate fashionable design, professional and comprehensive sports and health features, and efficient, practical smart experiences. Tailored to different user needs, Huawei has developed five product series to fulfil the diverse scenario requirements of all user groups—spanning smart living, scientific exercise, and health management. The HUAWEI WATCH Series incorporates cutting-edge smart technology, featuring standalone calling capabilities and smart vehicle control functions to enable an efficient, intelligent lifestyle. The newly launched HUAWEI WATCH 5 delivers enhanced intelligence, efficiency and convenience. Equipped with the innovative multi-sensing X-TAP technology, it unlocks new dimensions in health monitoring and tactile interaction. The HUAWEI WATCH FIT Series fulfils lightweight wear needs through its slim design and extensive sports functions, allowing users to fully enjoy daily life. Meanwhile, the HUAWEI WATCH GT Series combines exceptional battery life with fashionable aesthetics and professional sports health features, serving as a comprehensive wrist-worn fitness coach. For users who push boundaries and challenge extremes, the HUAWEI WATCH Ultimate Series delivers ultimate reliability with its rugged construction, advanced sports modes including 100-metre professional diving and outdoor expedition features, as well as advanced golf course mode, to bring cater to users' needs. Additionally, addressing hypertension management challenges, Huawei innovatively broke through wrist-based blood pressure technology to launch the HUAWEI WATCH D Series. Through its breakthrough 24-hour dynamic blood pressure monitoring function, it helps users measure and manage blood pressure anytime, anywhere, integrating professional-grade blood pressure health guardianship into daily life. Technological Innovation Driving Breakthroughs in Sports Health Technology Behind the satisfaction of users' sports health management needs lies Huawei wearables' continuous innovation investment. Huawei has established three Health Labs globally, leveraging capabilities from over ten Huawei research institutes to relentlessly explore the frontiers of sports health technology. In 2024, Huawei launched its new digital health & fitness paradigm—TruSense System—achieving higher accuracy and speed in vital sign data monitoring. In 2025, the TruSense System was upgraded again, fusing the advantages of fingertip and wrist detection to deliver a fuller, more accurate, and faster health monitoring experience, including 10-second fingertip blood oxygen readings and an increase in micro-body measurement indicators to 17 items. In the field of blood pressure management, Huawei pioneered the launch of the HUAWEI WATCH D, a wrist-based blood pressure monitor that obtained Class II medical device registration certification in China. Now this innovation included in the "Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)". As of now, Huawei wearable devices have obtained 7 domestic medical certifications and medical device certificates in 13 overseas countries/regions, with nearly 1000 patent applications in the smart wearables field. Huawei has collaborated with over 160 global professional institutions, conducted 300+ health research projects, and attracted over 17 million users to participate in health studies. Huawei accompanies global users to build sports health lifestyles together. In September 2023, Huawei initiated the "Light Up Your Rings" campaign, which has seen over 6 million global users participate, lighting up rings over 300 million times. In 2025, the fully upgraded "Active Rings" initiative was introduced, inspiring global users to move joyfully anytime, anywhere with Huawei wearables. The Active Rings campaign has already been held in Germany, Spain, and China, and beyond, where consumers jointly enjoyed active moments. It will progressively launch in APAC, Latin America, the Middle East, and other regions in the future.


Cision Canada
a day ago
- Cision Canada
Info-Tech LIVE 2025 Day 3 Highlights: Talent Strategies, the Future of AI and Quantum, and Key Takeaways From Final Day of Major IT Conference
The third and final day of Info-Tech LIVE 2025 in Las Vegas concluded the week by spotlighting bold leadership insights, forward-looking AI strategies, and transformative playbooks to guide IT organizations through exponential change over the coming year. TORONTO, June 13, 2025 /CNW/ - The final half-day of Info-Tech LIVE 2025 wrapped up with impactful keynotes focused on securing top talent, exploring groundbreaking technologies, and summarizing crucial insights gained over the course of the global research and advisory firm's annual conference. Thousands of IT leaders gathered at Bellagio in Las Vegas from June 10 to 12, 2025, and received strategic guidance on harnessing emerging trends and fostering resilient organizations that are ready for future challenges. Together, these final keynotes distilled the spirit of Info-Tech LIVE 2025 in Las Vegas: future-ready leadership grounded in practical action. Whether redefining how to approach talent, embracing the frontier of quantum computing, or synthesizing the week's most essential insights, each session delivered tangible takeaways to help organizations move forward with purpose. Key Highlights From Info-Tech LIVE 2025 in Last Vegas Day 3: 1. The Race for Talent: Build Over Buy Speaker: Carlene McCubbin, AVP of Research Development, Info-Tech Research Group The final day's keynote addressed the persistent IT talent crisis, arguing that traditional approaches to talent, which focused heavily on hiring and certifications, are no longer viable in today's fast-evolving landscape. Despite rising expectations for IT to lead innovation, only a small percentage of organizations currently meet these demands, with staff capacity, skills, and engagement cited as the top pain points. To tackle these issues, Carlene McCubbin introduced the AI x Talent Flywheel, a compounding framework that helps organizations rethink and redesign their talent systems to match the pace of change. Key takeaways Automate to Reclaim Time: Eliminate low-value tasks and reinvest saved time into growth by using AI to "automate the friction." Embed Learning into Work: Shift from episodic training to continuous, embedded learning using the 60-30-10 rule: 60% in-flow learning, 30% peer intelligence, and 10% formal updates. Expand with AI Agents: Scale through centaur leadership models where AI and humans collaborate symbiotically, expanding output without additional headcount. Build the Human Advantage: Focus on adaptability, creativity, and empathy, traits AI can't replicate, to unlock performance and future-proof teams. 2. The Future of AI & Quantum: What to Expect Next Speaker: Felix Schmidt, CEO & Founder, GenAIus Inc. In this provocative keynote, Felix Schmidt explored the convergence of agentic AI and quantum computing and their transformative implications for businesses and society. Using vivid comparisons between classical and quantum computing, Schmidt showcased the radical capabilities of quantum chips, highlighting that problems that traditional supercomputers would take longer than the universe's age can now be solved in mere minutes. Schmidt introduced the concept of "Q Day," the moment quantum computing becomes publicly accessible, and emphasized the urgency of preparing for it. Schmidt warned that encryption methods, blockchain systems, and even national infrastructure could be at risk, urging IT leaders to audit their encryption and begin AI agentic pilots immediately. Key Takeaways: Quantum computing represents a paradigm shift, not just an upgrade, that can drastically outperform classical machines in both speed and scale. AI agents are already transforming enterprise operations, offering unprecedented productivity gains when deployed effectively. Executive digital twins are becoming a reality, streamlining workflows and redefining leadership efficiency. The acceleration toward "Q Day" demands that organizations start preparing now by piloting agentic AI, auditing encryption, and staying informed on quantum advancements. 3. Five Key Takeaways from Info-Tech LIVE 2025 Speaker: Jeremy Roberts, Senior Director, Research & Content, Info-Tech Research Group This closing keynote brought together the major themes of the conference, offering actionable insights to carry forward. Jeremy Roberts highlighted how IT leaders can seize the moment to lead with confidence and transform uncertainty into opportunity. Key takeaways Don't just survive; thrive. Uncontrollable external events will always occur, but bold leadership during times of uncertainty can turn crises into catalysts for progress. Organizations can't out-hire the pace of change; they must out-learn it. This means fostering continuous learning, building strong peer networks, and prioritizing a healthy workplace culture over quick fixes. IT must first get its own house in order. Structured frameworks, such as the CIO Playbook, enable IT departments to optimize their performance and support enterprise-wide growth. Make IT's value visible. If an impact isn't seen, it's as if it hasn't happened. Clearly linking metrics to business value ensures alignment with all stakeholders, from chief financial officers (CFOs) to chief executive officers (CEOs). AI agents are not plug-and-play. Effective implementation requires rigorous planning and prototyping to avoid the many technical, operational, and integration-related pitfalls. Media Access to Info-Tech LIVE 2025 For media inquiries, including requests for interviews with featured speakers and experts to discuss what has been launched and explored at LIVE 2025, or for access to session recordings and additional content, please contact [email protected]. For conference-related press releases and images, please visit the online Info-Tech LIVE 2025 Media Kit. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software-buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact [email protected].


Cision Canada
a day ago
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.